Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study

Huang, HuiqiangHuiqiangHuangZhu, JunJunZhuMING YAOKim, Tae MinTae MinKimYoon, Dok HyunDok HyunYoonCho, Seok-GooSeok-GooChoEom, Hyeon SeokHyeon SeokEomLim, Soon ThyeSoon ThyeLimYeh, Su-PengSu-PengYehSong, YuqinYuqinSongKwong, Yok LamYok LamKwongKim, Jin SeokJin SeokKimJin, JieJieJinShi, YuankaiYuankaiShiKim, HyeJinHyeJinKimQing, MinMinQingZhou, TianyuanTianyuanZhouGao, GraceGraceGaoDong, ZongqiZongqiDongQi, MingMingQiKim, Won SeogWon SeogKim2023-03-272023-03-272021-02-151756-8722https://scholars.lib.ntu.edu.tw/handle/123456789/629790Natural killer/T-cell lymphoma (NKTCL) is a disease with limited treatment options and poor outcomes. Daratumumab monotherapy demonstrated clinical activity in a single-patient case report. We present data from the primary analysis of a phase 2 study of daratumumab monotherapy in relapsed or refractory (R/R) NKTCL.enCD38; Daratumumab; NK/T-cell lymphomaDaratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 studyjournal article10.1186/s13045-020-01020-y335889222-s2.0-85101436928WOS:000618196800001https://api.elsevier.com/content/abstract/scopus_id/85101436928